论文部分内容阅读
《星岛日报》报道:澳洲研究员对于寻找一种主要影响年轻女性的侵略性疾病,三阴性乳腺癌的治疗方法感乐观。尽管治疗方法仍处于老鼠测试阶段,但这种以两种经已在使用的药物为基础的治疗方案,有望可迅速开始人体临床试验。经过经年的研究,悉尼的开麟医学研究院(Kolling Institute of Medical Research)已找出蛋白如何帮助乳癌增长,及变得抗治疗性。研究员利用该认知,结合了两种药物已创造出一种他们声称在实验室中取得可观成效的新疗法。
The Sing Tao Daily reported: Australian researchers are optimistic about the treatment of triple-negative breast cancer in search of an aggressive disease that affects mainly young women. Although the treatment is still in the testing phase of mice, this two-drug-based treatment is expected to allow rapid clinical trials in humans. After years of research, the Kolling Institute of Medical Research in Sydney has figured out how proteins help breast cancer growth and become anti-therapeutic. Researchers use this awareness, combining two drugs, to create a new therapy they claim has yielded measurable results in the laboratory.